Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Neurogene Inc. (NGNE)
Company Research
Source: Business Wire
Ms. Shafer, a proven commercial leader in rare neurological diseases, will lead Neurogene’s commercial strategy and launch readiness for NGN-401 gene therapy for Rett syndromeMs. Mikail, President and CFO of Neurogene, adds strategic and operational leadership to the Board as Company advances key priorities NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, J.D., to its Board of Directors. Ms. Shafer brings more than 20 years of industry experience building and leading high-performing commercial organizations and launching therapies for rare neurological diseases. Ms. Mikail brings to the Board deep expertise in strategic transactions, capital formation, and corporate development, with a track record of building and posit
Show less
Read more
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Neurogene (NGNE) had its price target lowered by Canaccord Genuity Group Inc. from $200.00 to $180.00. They now have a "buy" rating on the stock.MarketBeat
- Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates [Yahoo! Finance]Yahoo! Finance
- Neurogene Reports Full Year 2025 Financial Results and Highlights Recent UpdatesBusiness Wire
NGNE
Earnings
- 3/24/26 - Miss
NGNE
Sec Filings
- 4/20/26 - Form 3
- 4/20/26 - Form 8-K
- 4/16/26 - Form ARS
- NGNE's page on the SEC website